Log in

Relevant bibliographies by topics / Anticoagulant effects / Journal articles

To see the other types of publications on this topic, follow the link: Anticoagulant effects.

Journal articles on the topic 'Anticoagulant effects'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anticoagulant effects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kreuter, Michael, Marlies S. Wijsenbeek, Martina Vasakova, et al. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." European Respiratory Journal 47, no. 6 (2016): 1776–84. http://dx.doi.org/10.1183/13993003.02087-2015.

Full text

Abstract:

Procoagulant and antifibrinolytic activity has been associated with idiopathic pulmonary fibrosis (IPF); however, investigation of anticoagulant therapy in IPF has suggested deleterious effects. This post hoc analysis evaluated the effect of medically indicated anticoagulation on mortality and other clinical outcomes in IPF.Patients randomised to placebo (n=624) from three controlled trials in IPF were analysed by oral anticoagulant use. End-points included all-cause and IPF-related mortality, disease progression, hospitalisation, and adverse events, over 1 year.At baseline, 32 (5.1%) patients

APA, Harvard, Vancouver, ISO, and other styles

2

Moore, Gary W., Savita Rangarajan, and Geoffrey F. Savidge. "The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies." Clinical and Applied Thrombosis/Hemostasis 14, no. 3 (2008): 332–37. http://dx.doi.org/10.1177/1076029607305099.

Full text

Abstract:

Lupus anticoagulants are a heterogeneous group of autoantibodies detected by their effects on phospholipid-dependent coagulation assays. Persistent lupus anticoagulants are associated with thrombotic disease, but not all are clinically significant. Antibody heterogeneity and reagent and test variability dictate that at least 2 tests, of different types, should be used to screen lupus anticoagulants. The objective of this study was to investigate whether the activated seven lupus anticoagulant assay detects clinically significant antibodies. Eighty-two patients with antiphospholipid syndrome (A

APA, Harvard, Vancouver, ISO, and other styles

3

Fareed, Jawed, Michael J. Moorman, Walter Jeske, and Debra Hoppensteadt. "Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs." Blood 122, no. 21 (2013): 4804. http://dx.doi.org/10.1182/blood.v122.21.4804.4804.

Full text

Abstract:

Introduction Defibrotide represents a single stranded mammalian DNA derived agent originally developed for anti-thrombotic and anti-ischemic indications. Defibrotide is currently used to treat or prevent failure of normal blood flow (Veno-occlusive disease, VOD) in the liver of patients who had bone marrow transplants or received drugs such as oral estrogens and mercatopurine. Defibrotide is a polypharmocologic agent with multiple sites of actions, which include anti-inflammatory and vaso-facilitatory effects. The purpose of this investigation is to determine potential interactions of defibrot

APA, Harvard, Vancouver, ISO, and other styles

4

Antovic, J., A. Antovic, E. M. Norberg, M. Berndtsson, and M. Skeppholm. "FRI0593 Effects of New (Direct) Oral Anticoagulants on Lupus Anticoagulant Assays." Annals of the Rheumatic Diseases 74, Suppl 2 (2015): 642.3–643. http://dx.doi.org/10.1136/annrheumdis-2015-eular.5847.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Young, Guy, Karyn E. Yonekawa, Peggy Nakagawa, Rachelle Blain, Amy E. Lovejoy, and Diane J. Nugent. "Recombinant Factor VIIa Reverses the Anticoagulant Effects of Argatroban, Bivalirudin, Fondaparinux, Enoxaparin, and Heparin as Assessed Ex Vivo by Thromboelastography." Blood 104, no. 11 (2004): 1867. http://dx.doi.org/10.1182/blood.v104.11.1867.1867.

Full text

Abstract:

Abstract BACKGROUND: The novel anticoagulants fondaparinux (Fond), argatroban (Arg), and bivalirudin (Biv) are being used increasingly for a variety of indications, even replacing heparin and warfarin in certain settings. While heparin and warfarin have antidotes (protamine and vitamin K, respectively), the newer agents lack known antidotes. Recombinant factor VIIa (rFVIIa) has reversed the effects of some novel anticoagulants in in vitro and animal studies. We evaluated the ability of rFVIIa to reverse the anticoagulant effects of Fond, Arg, Biv, unfractionated heparin (Hep), and enoxaparin (

APA, Harvard, Vancouver, ISO, and other styles

6

Kalinin, E. P., N. N. Buslaeva, and D. I. Boyarintsev. "Biological effects and assessment of acute toxicity of anticoagulants extracted from plants." Medical Science And Education Of Ural 21, no. 4 (2020): 27–29. http://dx.doi.org/10.36361/1814-8999-2020-21-4-27-29.

Full text

Abstract:

The aim of the study – was to study the biological effects and assess acute toxicity in an in vivo experimental study when injecting plant-derived effectors with an anticoagulant effect to laboratory animals. Materials and methods. As the studied effectors, plant anticoagulants obtained from the leaves of blueberry (Vaccinium myrtillus) and peloid, which were obtained in the previous studies, were used. The biological effect of effectors was evaluated by indicators characterizing coagulation and platelet hemostasis when administered to laboratory animals. Acute toxicity was assessed by the sur

APA, Harvard, Vancouver, ISO, and other styles

7

Blennerhassett, Richard, Emmanuel Favaloro, and Leonardo Pasalic. "Novel (Oral) Anticoagulant Challenges in Surgery." Seminars in Thrombosis and Hemostasis 43, no. 07 (2017): 706–15. http://dx.doi.org/10.1055/s-0037-1602667.

Full text

Abstract:

SummaryNon-vitamin K oral anticoagulants (NOACs) are a relatively recent therapeutic modality for the prevention of systemic thromboembolic complications of atrial fibrillation and the prevention and management of venous thromboembolic disease. Approved indications for this class of anticoagulants are likely to further expand as the results of ongoing and new clinical trials are published and clinical experience grows. Despite their convenience compared with traditional methods of anticoagulation, there remain a few potential pitfalls associated with their use in the perioperative setting. In

APA, Harvard, Vancouver, ISO, and other styles

8

Masood, Soofia, Debra Hoppensteadt, Josephine Cunanan, et al. "Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs." Blood 120, no. 21 (2012): 3421. http://dx.doi.org/10.1182/blood.v120.21.3421.3421.

Full text

Abstract:

Abstract Abstract 3421 Introduction: Most of the screening of the newer anticoagulant drugs is usually carried out in normal human blood derived plasma and its products. Therefore endogenous compositional factors in different patient groups which may result in altering the anticoagulant and antiprotease effects of these drugs are not taken into account. Recently an oral anti-IIa agent Dabigatran and an anti-Xa agent namely Rivaroxaban are approved for clinical usage in the US. An additional anti-Xa drug namely Apixaban is approved in Europe and is under review by the US FDA. The pharmacologic

APA, Harvard, Vancouver, ISO, and other styles

9

DIACONU, Camelia, Giorgiana DEDIU, Mădălina ILIE, and Mihaela Adela IANCU. "Treatment with new oral anticoagulants in the family medicine practice." Romanian Journal of Medical Practice 10, no. 4 (2015): 329–32. http://dx.doi.org/10.37897/rjmp.2015.4.4.

Full text

Abstract:

Vitamin K antagonists represented for more than 50 years the only oral anticoagulant treatment option, though encumbered by numerous food and drug interactions, with direct impact on the safety and efficacy of this treatment. The frequent complications of anticoagulant treatment with vitamin K antagonists led to the need for the emergence of new oral anticoagulants (NOAC). The main NOACs used today are dabigatran, rivaroxaban and apixaban. NOAC have a number of advantages over antivitamin K anticoagulants: fewer drug interactions, no food interactions, rapid onset of the anticoagulant action,

APA, Harvard, Vancouver, ISO, and other styles

10

Koyama, Takatoshi, and Misako Shibakura. "Anticoagulant Effects of Synthetic Retinoids." Leukemia & Lymphoma 31, no. 1-2 (1998): 71–80. http://dx.doi.org/10.3109/10428199809057586.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Tamada, Yasushi, Mitsuhiro Murata, Kenya Makino, Yoshinori Yoshida, Tadao Yoshida, and Toshio Hayashi. "Anticoagulant effects of sulphonated polyisoprenes." Biomaterials 19, no. 7-9 (1998): 745–50. http://dx.doi.org/10.1016/s0142-9612(97)00207-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Rea, C. A., S. R. J. Maxwell, D. J. Maslin, H. L. Thomason, and G. H. G. Thorpe. "Anticoagulant Effects of Antioxidant Capacity." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 33, no. 2 (1996): 174. http://dx.doi.org/10.1177/000456329603300218.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Silver, James H., Arlene P. Hart, Eliot C. Williams, et al. "Anticoagulant effects of sulphonated polyurethanes." Biomaterials 13, no. 6 (1992): 339–44. http://dx.doi.org/10.1016/0142-9612(92)90037-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Harenberg, Job, Svetlana Marx, Sandra Erdle, and Roland Krämer. "Determination of the anticoagulant effects of new oral anticoagulants: an unmet need." Expert Review of Hematology 5, no. 1 (2012): 107–13. http://dx.doi.org/10.1586/ehm.11.79.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Seheult, Jansen N., Michael P. Meyer, Franklin A. Bontempo, and Irina Chibisov. "The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays." American Journal of Clinical Pathology 147, no. 6 (2017): 632–40. http://dx.doi.org/10.1093/ajcp/aqx035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Fareed, Jawed, Debra Hoppensteadt, Omer Iqbal, et al. "Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents." Blood 120, no. 21 (2012): 3411. http://dx.doi.org/10.1182/blood.v120.21.3411.3411.

Full text

Abstract:

Abstract Abstract 3411 Defibrotide is a polydisperse mixture of porcine-derived single-stranded oligonucleotides which has been used for multiple clinical indications. Recent clinical trials of defibrotide indicate that this drug may provide benefits both for the treatment and prophylaxis of hepatic veno-occlusive disease (VOD) in hematopoietic stem cell therapy. In VOD it is believed that defibrotide exerts two distinct effects; 1. Endothelial cell protection and 2. Restoration of the thrombotic-fibrinolytic balance. Although antithrombotic in nature, defibrotide does not produce any systemic

APA, Harvard, Vancouver, ISO, and other styles

17

Spronk, Henri, and Leon Schurgers. "Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis." Thrombosis and Haemostasis 112, no. 11 (2014): 909–17. http://dx.doi.org/10.1160/th14-03-0268.

Full text

Abstract:

SummaryThe main purpose of anticoagulants is to diminish fibrin formation, thereby decreasing the risk of venous or arterial thrombosis. Vitamin K antagonist have been used for many decades in order to achieve reduced thrombotic risk, despite major drawbacks of this class of drugs such as cumbersome dossing and monitoring of anticoagulant status. To overcome these drawbacks of VKA, new classes of anticoagulants have been developed including oral anticoagulants for direct inhibition of either thrombin or factor Xa, which can be administrated in a fixed dose without monitoring. Coagulation facto

APA, Harvard, Vancouver, ISO, and other styles

18

Srinivasan, Divyamani, and Bree Watzak. "Anticoagulant Use in Real Time." Journal of Pharmacy Practice 26, no. 3 (2012): 270–79. http://dx.doi.org/10.1177/0897190012465950.

Full text

Abstract:

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). Each year, VTE affects about 300 000 to 600 000 people in the United States, and death is the first manifestation in one-fourth of this population.1{Beckman, 2010 #79} Moreover, approximately 10% of the US population has genetic factors that increase their risk for developing thrombosis.1 In addition to inherited disorders, factors that contribute to VTE include prolonged immobilization, trauma, surgery, cancer, and critically ill patients.2 Routine assessment and prophylaxis are recommended in the

APA, Harvard, Vancouver, ISO, and other styles

19

Ginsberg, Jeffrey S., Jack Hirsh, D. Christoper Turner, Mark N. Levine, and Robert Burrows. "Risks to the Fetus of Anticoagulant Therapy During Pregnancy." Thrombosis and Haemostasis 61, no. 02 (1989): 197–203. http://dx.doi.org/10.1055/s-0038-1646558.

Full text

Abstract:

SummaryThe use of anticoagulants during pregnancy is problematic because of the potential adverse effects to the mother and the fetus. Heparin does not cross the placenta, and thus, it was surprising that a recent report concluded that heparin therapy during pregnancy was as risky as oral anticoagulant therapy. Therefore, we performed a literature review of fetal/infant outcomes following anticoagulant therapy during pregnancy. We examined 186 reports which described fetal/infant outcomes in 1,325 pregnancies associated with anticoagulant therapy. The rates of adverse fetal/infant outcomes inc

APA, Harvard, Vancouver, ISO, and other styles

20

Brouwers, Jacobus R. B. J., Tom Schalekamp, Bob Wilffert, and Maarten Beinema. "Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon." Thrombosis and Haemostasis 100, no. 12 (2008): 1052–57. http://dx.doi.org/10.1160/th08-04-0116.

Full text

Abstract:

SummaryCoumarin oral anticoagulant drugs have proven to be effective for the prevention of thromboembolic events. World-wide, warfarin is the most prescribed drug. In Europe, acenocoumarol and phenprocoumon are also administered. Yet it has been proven that variant alleles of theVKORC1 and CYP2C9 genotypes influence the pharmacokinetics and pharmacodynamics of these drugs. The combination of these two variant genotypes is a major cause of the inter-individual differences in coumarin anticoagulant drug dosage. Individuals who test positive for both variant genotypes are at increased risk of maj

APA, Harvard, Vancouver, ISO, and other styles

21

Fisher, Campbell, Howald, and Warburton. "Anticoagulant Rodenticides, Islands and Animal Welfare Accountancy." Animals 9, no. 11 (2019): 919. http://dx.doi.org/10.3390/ani9110919.

Full text

Abstract:

Anticoagulant rodenticides are used to manage rodents in domestic, municipal, agricultural, and conservation settings. In mammals and birds, anticoagulant poisoning causes extensive hemorrhagic disruption, with the primary cause of death being severe internal bleeding occurring over days. The combined severity and duration of these effects represent poor welfare outcomes for poisoned animals. Noting a lack of formal estimates of numbers of rodents and nontarget animals killed by anticoagulant poisoning, the ready availability and worldwide use of anticoagulants suggest that very large numbers

APA, Harvard, Vancouver, ISO, and other styles

22

Lee, Agnes Y. Y. "Thrombosis in Cancer: An Update on Prevention, Treatment, and Survival Benefits of Anticoagulants." Hematology 2010, no. 1 (2010): 144–49. http://dx.doi.org/10.1182/asheducation-2010.1.144.

Full text

Abstract:

Abstract Thromboembolism is a common, complex, and costly complication in patients with cancer. Management has changed significantly in the past decade, but remains firmly dependent on the use of anticoagulants. Low-molecular-weight heparin is the preferred anticoagulant for prevention and treatment, although its limitations open opportunities for newer oral antithrombotic agents to further simplify therapy. Multiple clinical questions remain, and research is focusing on identifying high-risk patients who might benefit from primary thromboprophylaxis, treatment options for those with establish

APA, Harvard, Vancouver, ISO, and other styles

23

Kumano, Osamu, Kohei Akatsuchi, and Jean Amiral. "Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants." Biomedicines 9, no. 3 (2021): 264. http://dx.doi.org/10.3390/biomedicines9030264.

Full text

Abstract:

Anticoagulant drugs have been used to prevent and treat thrombosis. However, they are associated with risk of hemorrhage. Therefore, prior to their clinical use, it is important to assess the risk of bleeding and thrombosis. In case of older anticoagulant drugs like heparin and warfarin, dose adjustment is required owing to narrow therapeutic ranges. The established monitoring methods for heparin and warfarin are activated partial thromboplastin time (APTT)/anti-Xa assay and prothrombin time – international normalized ratio (PT-INR), respectively. Since 2008, new generation anticoagulant drugs

APA, Harvard, Vancouver, ISO, and other styles

24

Mosnier, Laurent O., Andrew J. Gale, Subramanian Yegneswaran, and John H. Griffin. "Activated protein C variants with normal cytoprotective but reduced anticoagulant activity." Blood 104, no. 6 (2004): 1740–44. http://dx.doi.org/10.1182/blood-2004-01-0110.

Full text

Abstract:

Abstract Recombinant activated protein C (APC), a well-defined anticoagulant enzyme, reduced mortality in severe sepsis patients in a phase 3 trial. However, 2 potent anticoagulants, antithrombin III and recombinant tissue factor pathway inhibitor, failed to do so, implying the physiologic relevance of APC's less well-defined anti-inflammatory and antiapoptotic activities. Recombinant APC therapy conveys an increased risk of serious bleeding complications due to APC anticoagulant activity. To generate recombinant APC variants with reduced risk of bleeding due to reduced anticoagulant activity,

APA, Harvard, Vancouver, ISO, and other styles

25

GARCIA, D., Y. C. BARRETT, E. RAMACCIOTTI, and J. I. WEITZ. "Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants." Journal of Thrombosis and Haemostasis 11, no. 2 (2013): 245–52. http://dx.doi.org/10.1111/jth.12096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Tripodi, Armando, Simon Braham, Barbara Scimeca, Marco Moia, and Flora Peyvandi. "How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues." Polish Archives of Internal Medicine 128, no. 6 (2018): 379–85. http://dx.doi.org/10.20452/pamw.4287.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Rolfe, Stephen, Stella Papadopoulos, and Katherine P. Cabral. "Controversies of Anticoagulation Reversal in Life-Threatening Bleeds." Journal of Pharmacy Practice 23, no. 3 (2010): 217–25. http://dx.doi.org/10.1177/0897190010362168.

Full text

Abstract:

Therapeutic anticoagulation with heparins, warfarin, and anti-Xa inhibitors carry an inherent risk of complications due to their multifaceted pharmacokinetic and pharmacodynamic properties as well as narrow therapeutic ranges. When an anticoagulated patient presents with a major or life-threatening bleed, immediate and effective therapy may be necessary to reverse the effects of the anticoagulant, minimize blood loss, and reduce patient morbidity and mortality. Optimal agents and strategies for anticoagulant reversal are limited, particularly for newer anticoagulants. The literature describing

APA, Harvard, Vancouver, ISO, and other styles

28

Chen, Huan, Jiaming Lei, Sicheng Liang, Gang Luo, Mingming Deng, and Muhan Lü. "Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis." Canadian Journal of Gastroenterology and Hepatology 2021 (April 21, 2021): 1–20. http://dx.doi.org/10.1155/2021/8859602.

Full text

Abstract:

Background and Aims. Portal vein thrombosis is a serious adverse event that occurs during liver cirrhosis. We performed a meta-analysis to evaluate the safety and efficacy of anticoagulant therapy and prophylactic anticoagulant therapy in cirrhosis patients with (/without) portal vein thrombosis. Methods. Eligible comparative studies were identified by searching the following electronic databases: PubMed, Embase, Cochrane Library, Web of Science, and CNKI. A meta-analysis was performed to calculate odds ratios and 95% confidence intervals using fixed-effects models. Recanalization and thrombus

APA, Harvard, Vancouver, ISO, and other styles

29

Deep, Akash, Mohammad Zoha, and Pompa Dutta Kukreja. "Prostacyclin as an Anticoagulant for Continuous Renal Replacement Therapy in Children." Blood Purification 43, no. 4 (2017): 279–89. http://dx.doi.org/10.1159/000452754.

Full text

Abstract:

Effective delivery of continuous renal replacement therapy (CRRT) depends on the longevity of the filter and circuit used in the CRRT machine. Safe and effective anticoagulation is crucial for maintaining the patency of these circuits. In children, heparin and citrate are the commonly used anticoagulants but they are limited by serious side effects and thus calls for meticulous monitoring. In conditions where neither of these can be used, prostacyclin can be an effective alternative. Prostacyclin is a platelet inhibitor that can be safely used as an efficient anticoagulant in CRRT. When combin

APA, Harvard, Vancouver, ISO, and other styles

30

GROSS, P., B. ESPOSITO, S. HAJMOHAMMADI, and N. SHWORAK. "Anticoagulant heparan sulfate mediates anti_inflammatory effects." Matrix Biology 25 (November 2006): S42—S43. http://dx.doi.org/10.1016/j.matbio.2006.08.118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

CHO, Hong Rae, and Hye-Seon CHOI. "Effects of Anticoagulant fromSpirodela polyrhizain Rats." Bioscience, Biotechnology, and Biochemistry 67, no. 4 (2003): 881–83. http://dx.doi.org/10.1271/bbb.67.881.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Carrasco, C., B. Campbell, and C. Shiach. "Effects of the lupus anticoagulant on the control of oral anticoagulant treatment." British Journal of Haematology 124, no. 4 (2004): 562–63. http://dx.doi.org/10.1111/j.1365-2141.2004.04813.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Patel, Anand, Richard P. Goddeau Jr, and Nils Henninger. "Newer Oral Anticoagulants: Stroke Prevention and Pitfalls." Open Cardiovascular Medicine Journal 10, no. 1 (2016): 94–104. http://dx.doi.org/10.2174/1874192401610010094.

Full text

Abstract:

Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its use is limited due to fear of hemorrhagic complications, unpredictable anticoagulant effects related to multiple drug interactions and dietary restrictions, a narrow therapeutic window, frequent difficulty maintaining the anticoagulant effect within a narrow therapeutic window, and the need for inconvenient monitoring. Several newer oral anticoagulants have been approved for primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation. These agents have several adv

APA, Harvard, Vancouver, ISO, and other styles

34

Gerasimenko, A. S., V. S. Gorbatenko, O. V. Shatalova, and V. I. Petrov. "Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage." Rational Pharmacotherapy in Cardiology 17, no. 2 (2021): 303–9. http://dx.doi.org/10.20996/1819-6446-2021-04-13.

Full text

Abstract:

Intracerebral hemorrhage (ICH) is severe and fatal complication of anticoagulant therapy with an incidence 0.3-0.7% per year. For patients with atrial fibrillation (AF) anticoagulants are administered for decreasing risk of stroke and systemic embolism. In this case the occurrence of intracranial bleeding is hard task for doctor. From the one side it is necessary to reverse the action of the drug for preventing the growth of hematoma. At the same time the discontinuation of therapy increases the risk of systemic embolism for patients with AF significantly. Clinical guidelines and studies have

APA, Harvard, Vancouver, ISO, and other styles

35

Sagris, Dimitrios, Georgios Georgiopoulos, Ioannis Leventis, et al. "Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis." Neurology 95, no. 5 (2020): e499-e507. http://dx.doi.org/10.1212/wnl.0000000000009823.

Full text

Abstract:

ObjectiveTo compare the efficacy and safety of oral anticoagulants vs antiplatelets in patients with stroke and atherosclerotic plaques in the aortic arch or cervical or intracranial arteries, collectively described as supracardiac atherosclerosis.MethodsWe searched PubMed and Scopus until August 28, 2019, for randomized trials comparing oral anticoagulants vs antiplatelets in patients with stroke and supracardiac atherosclerosis using the terms “anticoagulant or anticoagulation” and “antiplatelet or aspirin” and “randomized controlled trial or RCT” and “stroke or cerebral ischemia” and “aorti

APA, Harvard, Vancouver, ISO, and other styles

36

Jilma, Bernd, Judith M. Leitner, Florian B. Mayr, Christa Firbas, Rosemarie A. Reiter, and Peter Kalhs. "Anticoagulant and Anti-Inflammatory Effects of Recombinant Human Antithrombin in Man after LPS Challenge." Blood 106, no. 11 (2005): 1880. http://dx.doi.org/10.1182/blood.v106.11.1880.1880.

Full text

Abstract:

Abstract Background: Antithrombin (AT) had beneficial effects on mortality of septic patients in an a priori defined subpopulation of the Kypersept trial, which received no concomitant administration of heparin. Objectives: We hypothesized that recombinant human (rh)AT (without concomitant heparin) has anticoagulant properties and may decrease cytokine production in a well standardized model of human endotoxemia. Methods: This study was randomized, double-blind, placebo-controlled in parallel groups in 30 healthy male volunteers. The active treatment groups received bolus primed continuous inf

APA, Harvard, Vancouver, ISO, and other styles

37

Yamakawa, Kazuma, Yutaka Umemura, Shuhei Murao, Mineji Hayakawa, and Satoshi Fujimi. "Optimal Timing and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated Intravascular Coagulation." Clinical and Applied Thrombosis/Hemostasis 25 (January 1, 2019): 107602961983505. http://dx.doi.org/10.1177/1076029619835055.

Full text

Abstract:

Optimizing diagnostic criteria to detect specific patients likely to benefit from anticoagulants is warranted. A cutoff of 5 points for the International Society on Thrombosis and Haemostasis overt disseminated intravascular coagulation (DIC) scoring system was determined in the original article, but its validity was not evaluated. This study aimed to explore the optimal cutoff points of DIC scoring systems and evaluate the effectiveness of early intervention with anticoagulants. We used a nationwide retrospective registry of consecutive adult patients with sepsis in Japan to develop simulated

APA, Harvard, Vancouver, ISO, and other styles

38

Handayati, Anik, Syamsul Arifin, and Monica Putji Astuti. "Anticoagulant Activity of Dayak Onion Bulb (Eleutherine bulbosa) Extract on Human Blood Samples." Health Notions 5, no. 2 (2021): 46–48. http://dx.doi.org/10.33846/hn50202.

Full text

Abstract:

Cardiovascular disease can occur due to disruption of the hemostatic system by forming blood clots in blood vessels, or commonly known as deep vein thrombosis. The curative action that has been carried out in the form of heparin anticoagulant administration had many side effects such as bleeding, hematuria, thrombocytopenia, and hypersensitivity; therefore, alternative anticoagulant ingredients such as onion bulbs have emerged. Dayak onion bulb (Eleutherine bulbosa) is known to contain eleutherinol compound, which has anticoagulant activity. This study aims to determine the potential anticoagu

APA, Harvard, Vancouver, ISO, and other styles

39

Belic, Branislava, Marko Cincovic, Maja Dosenovic, Dragica Stojanovic, and Zorana Kovacevic. "The effects of different anticoagulants on biochemical parameters in blood of dairy cows." Veterinarski glasnik 69, no. 1-2 (2015): 13–20. http://dx.doi.org/10.2298/vetgl1502013b.

Full text

Abstract:

Routine analysis of blood parameters requires high precision. Therefore a significant number of methods and recommendations has been developed to ensure the obtaining of precise results. The aim of this study was to investigate whether the type of anticoagulant affects the values of biochemical parameters in the blood of dairy cows in relation to the values obtained from the serum. The study was carried out on 20 healthy cows of Holstein- Friesian breed in the second month of lactation. The blood was taken by venipuncture from v.coccigea. There were used five types of vacutainers as follows: f

APA, Harvard, Vancouver, ISO, and other styles

40

Ivanovic, Branislava, Bosiljka Vujisic-Tesic, Dragan Simic, and Danica Cvetkovic-Matic. "Nonoclusive thrombosis of mechanical mitral valve prosthesis caused by inadequate treatment of anticoagulant therapy resistance." Vojnosanitetski pregled 65, no. 11 (2008): 851–54. http://dx.doi.org/10.2298/vsp0811851i.

Full text

Abstract:

Background. Oral anticoagulants have been used in the prevention of thromboembolic complications for over six decades. A rare, but possible problem in the application of these medications could be resistance to them. Case report. We presented a patient with nonocclusive thrombosis of the mechanical mitral prosthesis due to inadequately treated resistance to peroral anticoagulant therapy. Resistance to oral anticoagulant medications was proven by an increased dosage of warfarin up to 20 mg and, after that, acenokumarol to 15 mg over ten days which did not lead to an increase in the internationa

APA, Harvard, Vancouver, ISO, and other styles

41

Puspitasari, Arina D., Daniel Dwi Christiananta Salean, Didik Hasmono, Rudy Hartono, and Meity Ardiana. "A study of anticoagulant therapy in patients with coronary artery disease." Journal of Basic and Clinical Physiology and Pharmacology 32, no. 4 (2021): 473–78. http://dx.doi.org/10.1515/jbcpp-2020-0486.

Full text

Abstract:

Abstract Objectives One of the methods used to treat coronary artery disease (CAD) is anticoagulant therapy, which involves administering anticoagulants to patients that inhibit the arrangement and actuation of clotting factors. Anticoagulant therapy in patients with CAD must be monitored and evaluated because its greatest side effect is the risk of bleeding. The research aimed to analyze anticoagulants used in therapy for CAD patients and identify potential adverse drug reactions and adverse drug interactions. Methods This was an observational study which collected data retrospectively at Bha

APA, Harvard, Vancouver, ISO, and other styles

42

Scarlatescu, Ecaterina, Dana Tomescu, and Sorin Stefan Arama. "Review. Anticoagulant Therapy in Sepsis. The Importance of Timing." Journal of Critical Care Medicine 3, no. 2 (2017): 63–69. http://dx.doi.org/10.1515/jccm-2017-0011.

Full text

Abstract:

Abstract Sepsis associated coagulopathy is due to the inflammation-induced activation of coagulation pathways concomitant with dysfunction of anticoagulant and fibrinolytic systems, leading to different degrees of haemostasis dysregulation. This response is initially beneficial, contributing to antimicrobial defence, but when control is lost coagulation activation leads to widespread microvascular thrombosis and subsequent organ failure. Large clinical trials of sepsis-related anticoagulant therapies failed to show survival benefits, but posthoc analysis of databases and several smaller studie

APA, Harvard, Vancouver, ISO, and other styles

43

Xu, Xiao, Xuechao Huang, Ying Zhang, et al. "Self-regulated hirudin delivery for anticoagulant therapy." Science Advances 6, no. 41 (2020): eabc0382. http://dx.doi.org/10.1126/sciadv.abc0382.

Full text

Abstract:

Pathological coagulation, a disorder of blood clotting regulation, induces a number of cardiovascular diseases. A safe and efficient system for the delivery of anticoagulants to mimic the physiological negative feedback mechanism by responding to the coagulation signal changes holds the promise and potential for anticoagulant therapy. Here, we exploit a “closed-loop” controlled release strategy for the delivery of recombinant hirudin, an anticoagulant agent that uses a self-regulated nanoscale polymeric gel. The cross-linked nanogel network increases the stability and bioavailability of hirudi

APA, Harvard, Vancouver, ISO, and other styles

44

Kalinin, E. P., D. I. Boyarintsev, and S. L. Galyan. "Preparation, purification and common characteristics of anticoagulant peptide from peloid." Kazan medical journal 96, no. 5 (2015): 824–28. http://dx.doi.org/10.17750/kmj2015-824.

Full text

Abstract:

Aim. To obtain the peloid extract containing peptide anticoagulant, to separate it from co-extracted compounds, to confirm the chemical structure of the purified anticoagulant, to characterize the amino acid profile and to evaluate its effect on blood clotting activity in vitro and the effect on hemostasis in laboratory animals. Methods. The anticoagulant was derived from lake Taraskul (Tyumen region) peloid. The effector was prepared and purified by original method including extraction, sedimentation of humic acids by salting-out, and removal of fulvic acids and low molecular weight fractions

APA, Harvard, Vancouver, ISO, and other styles

45

Kang, Tse Siang, Wan Chen, Leng Chuan Goh, and Manjunatha Kini. "Identification and characterisation of novel inhibitors on extrinsic tenase complex from Bungarus fasciatus (banded krait) venom." Thrombosis and Haemostasis 112, no. 10 (2014): 700–715. http://dx.doi.org/10.1160/th13-12-1063.

Full text

Abstract:

SummarySnake venoms are excellent sources of pharmacologically active proteins and peptides, and hence are potential sources of leads for drug developments. It has been previously established that krait (Bungarus genus) venoms contain mainly neurotoxins. A screening for anticoagulants showed that Bungarus fasciatus venom exhibits potent anticoagulant effect in standard clotting assays. Through sequential fractionation of the venom by size exclusion and high performance liquid chromatographies, coupled with functional screening for anticoagulant activities, we have isolated and purified two ant

APA, Harvard, Vancouver, ISO, and other styles

46

Kozek-Langenecker, S. "Modern anaesthetic techniques and anticoagulation." Hämostaseologie 26, S 02 (2006): S40—S49. http://dx.doi.org/10.1055/s-0037-1617081.

Full text

Abstract:

SummaryThe many possibilities for anticoagulant pharmacotherapy are constantly increasing. Anaesthetists and pain therapists are confronted with patients being treated with highly effective anticoagulants and/or platelet aggregation inhibitors for coronary heart disease, stroke or peripheral arterial occlusive disease. These patients in particular benefit from neuraxial blockade when undergoing cardiac surgery, revascularisation procedures or amputation. The anaesthetist needs to be familiar with the pharmacology, indications, and adverse effects of the various anti- and procoagulant substance

APA, Harvard, Vancouver, ISO, and other styles

47

Stringer, Kathleen A., and Joann Lindenfeld. "Hirudins: Antithrombin Anticoagulants." Annals of Pharmacotherapy 26, no. 12 (1992): 1535–40. http://dx.doi.org/10.1177/106002809202601211.

Full text

Abstract:

OBJECTIVE: To review the chemistry, pharmacology, available clinical data, and adverse effects of the hirudin anticoagulants. DATA SOURCES: A MEDLINE search and a review of recent scientific abstracts was conducted to identify pertinent literature. STUDY SELECTION: Focus was placed on studies conducted in humans. Because hirudin is still an investigational agent, however, relevant animal data, particularly pharmacokinetic studies and studies of preclinical efficacy, were also selected. DATA EXTRACTION: Data from both human and animal studies were evaluated; emphasis was placed on human trials.

APA, Harvard, Vancouver, ISO, and other styles

48

Mani, Helen, Alexander Kasper, and Edelgard Lindhoff-Last. "Measuring the anticoagulant effects of target specific oral anticoagulants—reasons, methods and current limitations." Journal of Thrombosis and Thrombolysis 36, no. 2 (2013): 187–94. http://dx.doi.org/10.1007/s11239-013-0907-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Antovic, Aleksandra, Eva-Marie Norberg, Maria Berndtsson, et al. "Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting." Thrombosis and Haemostasis 117, no. 09 (2017): 1700–1704. http://dx.doi.org/10.1160/th17-03-0204.

Full text

Abstract:

SummaryLaboratory diagnosis of lupus anticoagulant (LA) is based on prolongation in at least one coagulation assay (diluted Russell’s viper venom time – dRVVT or activated partial thromboplastin time – aPTT), which normalises after addition of phospholipids. Both assays may be influenced by anticoagulants and therefore LA should not be tested during warfarin or heparin treatment. It has been shown (primarily in vitro) that direct oral anticoagulants (DOACs – dabigatran [DAB], rivaroxaban [RIV] and apixaban [API]) may also influence LA testing. We tested the effects of DOACs on assays routinely

APA, Harvard, Vancouver, ISO, and other styles

50

Gantioqui, Jorell, Ivan Stevic, Paul Y. Kim, Keith K. Lau, Anthony K. C. Chan, and Howard H. W. Chan. "An in-Vitro Model Using Thromboelastography to Evaluate the Effects of Anticoagulants On Clot Formation in Plasma Enriched with Autologous Platelets." Blood 120, no. 21 (2012): 1091. http://dx.doi.org/10.1182/blood.v120.21.1091.1091.

Full text

Abstract:

Abstract Abstract 1091 Background: In the presence of thrombocytopenia, antithrombotic therapy in patients with thrombosis is a challenge for the managing physicians. Current guidelines are based on anecdotal data and expert opinion. Hereby, we used an in-vitro model with thrombelastography (TEG) to study the interactions of anticoagulants with plasma clotting proteins and varying concentrations of platelets. The objective of this study is to better elucidate the range of platelet concentrations in plasma which will permit clot formation in the presence of anticoagulant. Methods: Fresh human p

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!